Inhibition of CCR3 is expected to provide a robust therapeutic approach for the treatment of aging-associated neuroinflammatory diseases, particularly those associated with excessive T-cell infiltration such as multiple sclerosis and Parkinson’s disease. This evidence concerns the gene CCR3 and Parkinson disease.